Dose optimisation of anti-infectives in patients post-lung transplant

A domestic PhD scholarship is available from the NHMRC-funded Centre of Research Excellence in Redefining Antimicrobial Use to Reduce Resistance - CRE REDUCE - at The University of Queensland for a motivated and independent healthcare practitioner to improve pharmacotherapy for patients that have received a lung transplant. Due to the significance of the transplant procedure and the associated immunosuppression, use of maximally effective antibacterial therapy is very important to improve patient outcomes. This PhD will seek to innovate antibacterial dosing in these patients using pharmacokinetic studies and will provide the opportunity for the student to learn advanced pharmacokinetic modelling skills as well as develop skills in project design, project management and statistical analysis. Ideally the applicant should hold an Honours or Master’s degree with adequate previous research experience. The projects would be conducted at The Prince Charles Hospital in Brisbane, Australia.

This PhD project is related to Antimicrobial pharmacokinetics in patients with cystic fibrosis, lung and bone marrow transplant.